Trial Profile
A Phase II Study of Neoadjuvant Pemetrexed, Carboplatin and Bevacizumab in Unresectable, Locally Advanced Lung Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Jul 2016
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms GASTO-1001
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 23 Dec 2015 Results published in the Cancer
- 03 Sep 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.